The incidence of inflammatory bowel disease (IBD) has increased globally, 1 which has redirected the health care system’s focus toward safe and affordable pharmacologic interventions. As the patents ...

This article originally appeared on The Center for Biosimilars®. A study confirmed the effectiveness and safety of GP2017 in patients with inflammatory bowel disease (IBD) who were naïve to adalimumab ...

Please provide your email address to receive an email when new articles are posted on . Results showed 22.7% of patients who reinitiated infliximab after biosimilar use discontinued treatment due to ...

Data from the PRospective Observational cohort Study on patients with Inflammatory bowel disease receiving Therapy with BIOsimilars (PROSIT-BIO) in patients with ulcerative colitis (UC) and Crohn’s ...

Please provide your email address to receive an email when new articles are posted on . “We can now say with confidence, while certainly this isn’t necessarily the way most of us practice, that you ...

Switching between infliximab biosimilar SB2 and the reference product did not affect clinical disease activity or safety in IBD patients. No significant changes were observed in clinical outcomes, ...

LAS VEGAS -- In patients with inflammatory bowel disease who lost response after infliximab (Remicade) induction, escalating the maintenance dose of the subcutaneous infliximab biosimilar CT-P13 ...

Rheumatologist Marcus Snow, MD, is comfortable with prescribing biosimilars as a first-line, first-time biologic, and discussing them with patients. "If a biosimilar is on the market, it has gone ...

There are critical gaps in biosimilar adoption for pediatric patients, focusing on safety, regulatory challenges, and the ...